Published in Lab Business Week, July 17th, 2005
According to a recent study from the United States as reported in the journal Vaccine, "Lines of experimental evidence indicate that induction of humoral immune responses in transgenic mouse models of Alzheimer disease (AD) by repeated injection of synthetic amyloid beta-protein (A-beta) is effective in prevention and clearance of deposits of A-beta aggregates in the brain of the mice."
"We have tested a non-injection modality whereby replication-defective adenovirus vectors encoding A-beta or the 99-amino acid carboxyl...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week